Advertisement

Monitoring of Everolimus Trough Concentrations for Achieving Optimal Tolerance in the Management of Tuberous Sclerosis Complex

      Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the development of a variety of benign tumors along with an increased risk of malignancy. Mechanism of disease is related to the mTOR pathway.
      • Jozwiak J.
      • Jozwiak S.
      • Wlodarski P.
      Possible mechanisms of disease development in tuberous sclerosis.
      In spite of this, individual features have different natural histories, and it is difficult to predict the extent to which a child with newly diagnosed disease is affected.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Pediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jozwiak J.
        • Jozwiak S.
        • Wlodarski P.
        Possible mechanisms of disease development in tuberous sclerosis.
        Lancet. 2008 Jan; 9: 73-79
        • Curran M.P.
        Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
        Pediatr Drugs. 2012; 14: 51-60
        • Bissler J.J.
        • Kingswood J.C.
        • Radzikowska E.
        • et al.
        Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
        Lancet. 2013; 9: 817-824
        • Danesi Romano
        • Boni Joseph P.
        • Ravaud Alain
        Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
        Cancer Treat Rev. 2013; 39: 784-792